Respiratory Disease

Predictive role of IL-17A in refractory Mycoplasma pneumoniae pneumonia in children

  • Longfei GAO ,
  • Jingli ZHANG ,
  • Xiaojie WU ,
  • Huifang WU ,
  • Chenchu DUAN ,
  • Juncong KANG ,
  • Zhongping ZHANG
Expand
  • Respiratory Department, Hebei Children's Hospital, Shijiazhuang 050000, Hebei, China

Received date: 2022-01-06

  Online published: 2023-05-10

Abstract

Objective To explore the predictive value of blood interleukin (IL)-17A in children with refractory Mycoplasma pneumoniae pneumonia (RMPP). Methods Clinical data of children with Mycoplasma pneumoniae pneumonia (MPP) admitted from January 2019 to October 2021 were retrospectively analyzed. The enrolled children were divided into the MPP and the RMPP group. The differences of infection-related indexes between the two groups were compared, and the value of these indicators in predicting RMPP was evaluated by ROC curves. Results A total of 63 children with MPP were included in the study, including 42 cases in MPP group and 21 cases in RMPP group. There were 43 males and 20 females with a median age of 4.9(1.8-12.0) years and no significant differences was found in gender and age between the two groups (P>0.05). The proportion of lobar consolidation, pleural effusion, moxifloxacin, glucocorticoid and bronchoscopy in RMPP group were higher than those in MPP group (P<0.05). Also, IL-17A, IL-18, LDH and ferritin levels in RMPP group were higher (P<0.05). The area under ROC curve (AUC) of IL-18 and IL-17A in predicting RMPP were 0.85, 0.81, 0.80 and 0.69 in the RMPP group, respectively, with corresponding cut-off values of 472.0 pg/mL, 13.4 pg/mL,389.0 UI/mL, and 251.0 pg/mL, respectively. Conclusions Serum IL-17A≥13.4 pg/mL and IL-18≥472 pg/mL were relatively accurate predictors of refractory mycoplasma pneumonia in children, and IL-18 has higher predictive efficacy.

Cite this article

Longfei GAO , Jingli ZHANG , Xiaojie WU , Huifang WU , Chenchu DUAN , Juncong KANG , Zhongping ZHANG . Predictive role of IL-17A in refractory Mycoplasma pneumoniae pneumonia in children[J]. Journal of Clinical Pediatrics, 2023 , 41(5) : 366 -369 . DOI: 10.12372/jcp.2023.22e0032

References

[1] Rueda ZV, Aguilar Y, Maya MA, et al. Etiology and the challenge of diagnostic testing of community-acquired pneumonia in children and adolescents[J]. BMC Pediatr, 2022, 22(1): 169.
[2] Liu JR, Lu J, Dong F, et al. Low bacterial co-infection invalidates the early use of non-anti-Mycoplasma pneumoniae antibiotics in pediatric refractory Mycoplasma pneumoniae pneumonia patients[J]. Front Pediatr, 2018, 6: 296.
[3] Tsai TA, Tsai CK, Kuo KC, et al. Rational stepwise approach for Mycoplasma pneumoniae pneumonia in children[J]. J Microbiol Immunol Infect, 2021, 54(4): 557-565.
[4] McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 family of cytokines in health and disease[J]. Immunity, 2019, 50(4): 892-906.
[5] Choi YJ, Jeon JH, Oh JW. Critical combination of initial markers for predicting refractory Mycoplasma pneumoniae pneumonia in children: a case control study[J]. Respir Res, 2019, 20(1):193.
[6] Ding W, Zhang XY, Pan M, et al. Interleukin-17A promotes the formation of inflammation in the lung tissues of rats with pulmonary fibrosis[J]. Exp Ther Med, 2015, 10(2): 491-497.
[7] Yang M, Meng F, Wang K, et al. Interleukin 17A as a good predictor of the severity of Mycoplasma pneumoniae pneumonia in children[J]. Sci Rep, 2017, 7(1): 12934.
[8] 中华医学会儿科学分会呼吸学组,《中华实用儿科临床杂志》编辑委员会. 儿童肺炎支原体肺炎诊治专家共识(2015 年版)[J]. 中华实用儿科临床杂志, 2015, 30(17): 1304-1308.
[9] 丁斌, 李小兵, 李雷雷. Th17/Treg细胞在儿童支原体肺炎发病中的作用[J]. 中国卫生检验杂志, 2017, 27(12): 1758-1760.
[10] Song X, He X, Li X, et al. The roles and functional mechanisms of interleukin-17 family cytokines in mucosal immunity[J]. Cell Mol Immunol, 2016, 13(4): 418-431.
[11] Veldhoen M. Interleukin 17 is a chief orchestrator of immunity[J]. Nat Immunol, 2017, 18(6): 612-621.
[12] Li Q, Gu Y, Tu Q, et al. Blockade of Interleukin-17 restrains the development of acute lung injury[J]. Scand J Immunol, 2016, 83(3): 203-211.
[13] Li G, Fan L, Wang Y, et al. High co-expression of TNF-αand CARDS toxin is a good predictor for refractory Mycoplasma pneumoniae pneumonia[J]. Mol Med, 2019, 25(1):38.
[14] Izumikawa K. Clinical features of severe or fatal Mycoplasma pneumoniae pneumonia[J]. Front Microbiol, 2016, 7: 800.
[15] 李姣. 重症肺炎支原体肺炎临床特征与IL-18、Th1细胞因子疾病发展关系的研究[D]. 天津: 天津医科大学, 2018.
[16] Su M, Wang Q, Li D, et al. Prevalence and clinical characteristics of hospitalized children with community-acquired Mycoplasma pneumoniae pneumonia during 2017/2018, Chengde, China[J]. Medicine (Baltimore), 2021, 100(5): e23786.
[17] 赵兰杰. 支原体肺炎患儿免疫功能的变化及其意义[D]. 山西医科大学, 2018.
[18] Principi N, Esposito S. Macrolide-resistant Mycoplasma pneumoniae: its role in respiratory infection[J]. J Antimicrob Chemother. 2013, 68(3):506-511.
[19] Wirth S, Emil SGS, Engelis A, et al. Moxifloxacin in pediatric patients with complicated intra-abdominal infections: results of the MOXIPEDIA randomized controlled study[J]. Pediatr Infect Dis J, 2018, 37(8): e207-e213.
Outlines

/